A Study of SPY001-001 in Healthy Volunteers

Phase 1 Completed 96 enrolled Spyre Therapeutics, Inc. Altasciences Company Inc. · collab

RandomizedSequentialQuadruple-blindBasic science

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants.

Timeline

Start: 2024-06-06
Primary completion: 2026-03-10
Completion: 2026-03-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPY001-001	Unknown	—	—

Indications

No indication recorded.